I can't speculate Blane about management's reasoning or lack thereof. I can say this: Before now, I was neutral with them. I hadn't seen any deleterious decisions. They seemed to be on a good course. But this is a huge one-off blunder and that's one too many of this proportion.
IMO they need to do something and quickly to clarify the issue. If they do that, even if they were to take full responsibility for the blunder, it would be a worthy step.
At the moment, with so many excellent biotech opportunities out there, I've got one foot out the door.
Kind regards,
Minding
News 
Market Data 
Discover 
AI
